36 results on '"Bresnik, M."'
Search Results
2. EE223 Cost-Effectiveness of Olorofim in Invasive Aspergillosis Patients Lacking Suitable Alternative Treatment Options from a US Payer Perspective
3. THE EFFECT OF BURKHOLDERIA COLONY MORPHOLOGY IN CYSTIC FIBROSIS (CF) PATIENTS WITH CHRONIC BURKHOLDERIA SPECIES IN A RANDOMIZED TRIAL OF AZTREONAM FOR INHALATION SOLUTION (AZLI): 307
4. LUNG FUNCTION IN CYSTIC FIBROSIS (CF) PATIENTS WITH CHRONIC BURKHOLDERIA (BURK) SPECIES INFECTION OVER THE COURSE OF A PROSPECTIVE, RANDOMIZED TRIAL OF AZTREONAM FOR INHALATION SOLUTION (AZLI): 310
5. AZTREONAM FOR INHALATION SOLUTION (AZLI) CLINICAL DEVELOPMENT PROGRAM: COMBINED PEDIATRIC EXPERIENCE: 305
6. LUNG FUNCTION IMPROVEMENT WITH AZTREONAM FOR INHALATION SOLUTION (AZLI) IN THE SINGLEARM EXTENSION OF A RANDOMIZED TRIAL OF INHALED ANTIPSEUDOMONAL ANTIBIOTICS IN PATIENTS WITH CYSTIC FIBROSIS (CF) AND PSEUDOMONAS AERUGINOSA INFECTION: 278
7. EFFECTS OF CONTINUOUS AZTREONAM FOR INHALATION SOLUTION (AZLI) USE ON PATHOGENS AND ANTIBIOTIC SUSCEPTIBILITY IN CYSTIC FIBROSIS (CF) PATIENTS WITH CHRONIC BURKHOLDERIA SPECIES INFECTION: 257★
8. AZTREONAM FOR INHALATION SOLUTION (AZLI) IN CYSTIC FIBROSIS (CF) PATIENTS WITH CHRONIC BURKHOLDERIA SPECIES (BURK) INFECTION: INITIAL RESULTS FROM A RANDOMIZED, PLACEBO-CONTROLLED TRIAL: 234
9. CHANGE IN FEV1% PREDICTED IN RESPONSE TO AZTREONAM FOR INHALATION SOLUTION (AZLI) VS. TOBRAMYCIN INHALATION SOLUTION (TIS) IN AN ACTIVE COMPARATOR STUDY: RESPONDER ANALYSES: 216
10. Treatment outcome of invasive mould disease after sequential exposure to azoles and liposomal amphotericin B
11. Liposomal amphotericin B (AmBisome®) efficacy in confirmed invasive aspergillosis and other filamentous fungal infections in immunocompromised hosts: a pooled analysis
12. Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia
13. Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia
14. Open label study of inhaled aztreonam for pseudomonas eradication in children with cystic fibrosis: The ALPINE study
15. ePS06.5 Post-hoc review of outcomes in patients switching from tobramycin for nebulization solution (TNS) to aztreonam lysine for inhalation (AZLI)
16. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial
17. Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease
18. 110 Aztreonam for inhalation solution (AZLI) for eradication of new onset Pseudomonas aeruginosa ( PA ) infection in children with cystic fibrosis (CF): Evaluation of treatment failures
19. WS02.2 Aztreonam for inhalation solution (AZLI) for eradication of new onset Pseudomonas aeruginosa ( PA ) infection in children with cystic fibrosis (CF): Results of facemask vs. nebulizer mouthpiece use
20. 61 Baseline data from a prospective 5-year registry study to monitor susceptibility to aztreonam of Pseudomonas aeruginosa (PA) isolates from patients with cystic fibrosis (CF) in the United States
21. WS5.4 Aztreonam for inhalation solution (AZLI) in cystic fibrosis (CF) patients with chronic Burkholderia species (BURK) infection: final results from a randomized, placebo-controlled trial
22. 58 No antibiotic cross-resistance after 1 year of continuous aztreonam for inhalation solution (AZLI) in cystic fibrosis (CF) patients (pts) with chronic Burkholderia (BURK) infection
23. 86* Lung function improvement with aztreonam 75 mg powder and solvent for nebuliser solution (AZLI) in a single-arm extension of a randomized trial of inhaled antipseudomonal antibiotics in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa infection
24. 107 In vitro susceptibility of Pseudomonas aeruginosa (PA) does not predict clinical response to aztreonam 75 mg powder and solvent for nebuliser solution (AZLI): a responder analysis in subjects with cystic fibrosis (CF)
25. 84 Aztreonam 75 mg powder and solvent for nebuliser solution (AZLI) in cystic fibrosis (CF) patients with chronic Burkholderia species (Burk) infection: baseline demographics and microbiology from a randomized, placebo-controlled trial
26. Treatment outcome of invasive mould disease after sequential exposure to azoles and liposomal amphotericin B
27. Liposomal amphotericin B (AmBisome®) efficacy in confirmed invasive aspergillosis and other filamentous fungal infections in immunocompromised hosts: a pooled analysis.
28. ALPINE2: Efficacy and safety of 14-day vs 28-day inhaled aztreonam for Pa eradication in children with cystic fibrosis.
29. Pseudomonas aeruginosa Susceptibility Patterns and Associated Clinical Outcomes in People with Cystic Fibrosis following Approval of Aztreonam Lysine for Inhalation.
30. Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia.
31. Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis.
32. Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: a placebo-controlled trial.
33. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial.
34. Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease.
35. A safety and feasibility study comparing an intermittent high dose with a daily standard dose of liposomal amphotericin B for persistent neutropenic fever.
36. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.